Detalhe da pesquisa
1.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 643-654, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857412
2.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 655-664, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857414
3.
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Eur J Cancer
; 201: 113585, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402687
4.
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Eur J Cancer
; 189: 112900, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37277264
5.
Prognostic and predictive value of ß-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Eur J Cancer
; 165: 97-112, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220182
6.
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III).
Cancers (Basel)
; 13(10)2021 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34070224
7.
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
Eur J Cancer
; 153: 213-222, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34214936
8.
Sentinel node biopsy for melanoma: The medical oncology perspective.
Aust Fam Physician
; 44(12): 875-6, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27505912
9.
Intratumoural immunotherapies in oncology.
Eur J Cancer
; 127: 1-11, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31962197
10.
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
Pigment Cell Melanoma Res
; 33(2): 358-365, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31587511
11.
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
J Clin Oncol
; 38(33): 3925-3936, 2020 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32946353
12.
Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature.
Melanoma Res
; 29(3): 333-337, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30730328
13.
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.
Pigment Cell Melanoma Res
; 32(4): 553-563, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30767428
14.
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eur J Cancer
; 116: 148-157, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200321
15.
Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.
Clin Cancer Res
; 24(5): 1090-1102, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29196297
16.
Reply to E. Hindié.
J Clin Oncol
; 39(8): 944-946, 2021 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33492998
17.
Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review.
Melanoma Res
; 24(4): 349-53, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24709889